Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19.taNK
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19.taNK is an off-the-shelf, chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy derived from the proprietary NK-92 cell line. Developed by NantKwest (now ImmunityBio), the therapy is designed to target and eliminate B-cells expressing the CD19 antigen, which is a hallmark of various hematologic malignancies. Unlike autologous CAR-T cell therapies that require patient-specific manufacturing, CD19.taNK is an allogeneic product that can be administered without the need for HLA matching, potentially offering a faster and more cost-effective treatment option. The mechanism involves the CAR-mediated recognition of CD19, triggering the NK cells' natural cytotoxic machinery, including the release of perforins and granzymes, to induce apoptosis in malignant cells.
- Other names
- CD19-targeted activated Natural Killer cellsCD-19-targeted activated Natural Killer cellsCD 19-targeted activated Natural Killer cellsCD19-CAR NK-92 cellsCD-19-CAR NK-92 cellsCD 19-CAR NK-92 cells
02
Targets
Beyond the preview
Go deeper on CD19.taNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19.taNK.